279 related articles for article (PubMed ID: 28665498)
1. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
[TBL] [Abstract][Full Text] [Related]
4. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
5. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis.
Hsu SJ; Wang SS; Hsin IF; Lee FY; Huang HC; Huo TI; Lee WS; Lin HC; Lee SD
Clin Sci (Lond); 2014 May; 126(9):633-44. PubMed ID: 24063570
[TBL] [Abstract][Full Text] [Related]
6. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
7. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
Feng HQ; Weymouth ND; Rockey DC
Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G27-33. PubMed ID: 19299580
[TBL] [Abstract][Full Text] [Related]
8. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Oberti F; Pilette C; Rifflet H; Maïga MY; Moreau A; Gallois Y; Girault A; le Bouil A; Le Jeune JJ; Saumet JL; Feldmann G; Calès P
J Hepatol; 1997 Jun; 26(6):1363-71. PubMed ID: 9210625
[TBL] [Abstract][Full Text] [Related]
9. LPS exacerbates endothelin-1 induced activation of cytosolic phospholipase A2 and thromboxane A2 production from Kupffer cells of the prefibrotic rat liver.
Miller AM; Masrorpour M; Klaus C; Zhang JX
J Hepatol; 2007 Feb; 46(2):276-85. PubMed ID: 17161492
[TBL] [Abstract][Full Text] [Related]
10. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
11. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
[TBL] [Abstract][Full Text] [Related]
13. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
14. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
[TBL] [Abstract][Full Text] [Related]
15. An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats.
Gandhi CR; Nemoto EM; Watkins SC; Subbotin VM
Liver; 1998 Feb; 18(1):39-48. PubMed ID: 9548266
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.
Klein S; Herath CB; Schierwagen R; Grace J; Haltenhof T; Uschner FE; Strassburg CP; Sauerbruch T; Walther T; Angus PW; Trebicka J
PLoS One; 2015; 10(9):e0138732. PubMed ID: 26406236
[TBL] [Abstract][Full Text] [Related]
17. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats.
Yang YY; Lee TY; Huang YT; Chan CC; Yeh YC; Lee FY; Lee SD; Lin HC
Liver Int; 2012 Jan; 32(1):48-57. PubMed ID: 22098317
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.
Wang L; He FL; Liu FQ; Yue ZD; Zhao HW
World J Gastroenterol; 2015 Aug; 21(32):9544-53. PubMed ID: 26327762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
